CDC- BRFSS – ACBS 19-21 Child Prevalence Table 8

Table 8: Estimated percent using inhaled short acting beta agonists among children1 with current2 asthma status by state/territory – BRFSS Asthma Call-back Survey, United States, 2019-2021.
State/Territory Current
Sample
size±
% SE§ 95% CI
California 56 55.7 8.8 (38.5 – 72.9)
Connecticut 163 52.4 6.4 (39.9 – 64.9)
Florida 113 26.7 7.5 (12.0 – 41.4)
Georgia 95 41.3 8.4 (24.8 – 57.8)
Hawaii 62 48.4 8.8 (31.2 – 65.6)
Indiana 128 46.5 5.8 (35.1 – 57.9)
Kansas 111 34.6 5.3 (24.2 – 45.0)
Massachusetts 61 64.2 8.2 (48.1 – 80.3)
Michigan 165 43.0 5.1 (33.0 – 53.0)
Minnesota 159 47.6 5.3 (37.2 – 58.0)
Missouri 134 65.7 6.1 (53.7 – 77.7)
Nebraska 125 53.2 6.6 (40.3 – 66.1)
New Hampshire 103 37.6 6.0 (25.8 – 49.4)
New York 120 41.5 8.0 (25.8 – 57.2)
Ohio 103 56.5 6.8 (43.2 – 69.8)
Pennsylvania 58 43.5 7.7 (28.4 – 58.6)
Rhode Island 77 46.8 8.5 (30.1 – 63.5)
Texas 172 57.1 7.0 (43.4 – 70.8)
Utah 199 47.7 4.7 (38.5 – 56.9)
Vermont 114 68.2 5.6 (57.2 – 79.2)
Wisconsin 73 56.9 8.6 (40.0 – 73.8)
21 States / Area 2,453 49.2 2.5 (44.3 – 54.1)
Median 48.1
Range 26.7-68.2

1 Aged < 18 years

2 “Yes” response to “Do you still have asthma?”

± Sample size for multiple years of participation. Responses of “Don’t Know” and “Refused” are excluded.

§ Standard error

Confidence interval

Link for Summary Data Quality Report: https://www.cdc.gov/brfss/acbs/2021/pdf/sdq_report_acbs_21-508.pdf